Comprehensive Financial Consultants Institutional’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Comprehensive Financial Consultants Institutional’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-57	Closed	-$1K	–	203
2021 Q4	$1K	Buy	+57	New	+$1.58K	﹤0.01%	444

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Comprehensive Financial Consultants Institutional's CNCR Position: Q1 2022 in Review

Comprehensive Financial Consultants Institutional sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q1 2022, closing a stake of 57 shares — an estimated $1K sold.

Comprehensive Financial Consultants Institutional first reported a position in CNCR in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 20 funds tracked by Wall St. Rank hold CNCR as of Q1 2022.

Comprehensive Financial Consultants Institutional reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q1 2022 after selling out during the quarter.
Comprehensive Financial Consultants Institutional sold 57 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q1 2022, an estimated $1K.
Comprehensive Financial Consultants Institutional first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2021 and held it in 1 quarter.
Comprehensive Financial Consultants Institutional's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $1K in Q4 2021.
20 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2022.

Based on Comprehensive Financial Consultants Institutional's 13F filing for Q1 2022, filed 11 May 2022.